Bloom Science to Present at the Sachs 1st Annual Biopharma Obesity Innovation Forum

SAN DIEGO, Calif., January 9, 2025 – Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that its Chief Executive Officer, Christopher Reyes, Ph.D., will deliver a presentation focused on Bloom’s obesity program and clinical data at the Sachs Associates 1st Annual Biopharma Obesity Innovation Forum. The conference will take place January 11, 2025, in San Francisco, California preceding the 43rd Annual J.P. Morgan Healthcare Conference.

Details of the presentations are as follows:

• 1st Annual Biopharma Obesity Innovation Forum
  Details: Dr. Reyes will deliver a presentation and participate in 1-on-1 meetings
  Conference dates: January 11, 2025
  Presentation Timing: 2:20 p.m. PST

About Bloom Science, Inc. 

Bloom Science, Inc. is a clinical-stage biotech company focused on the development of novel first-in-class therapies for the treatment of metabolic and neurological disorders. Bloom’s research and development activities leverage its expertise in gut-brain axis biology, metabolism and the microbiome to develop innovative therapeutics designed to improve patients’ lives. Bloom’s clinical programs include BL-001, a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. Bloom Science is advancing a deep pipeline of programs, focused in obesity, Dravet syndrome and DEEs, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.